Dr. Li Wang is currently Senior Director and the Head of Statistical Innovation group in AbbVie.  Prior to this senior leadership role, he led Immunology and Solid Tumor statistical design and strategy discussions and multiple innovation projects in AbbVie Development Design Center from 2017 to 2019. He joined AbbVie in 2013 as the lead statistician for RINVOQ RA phase 2 and multiple other compounds in early immunology in RA, OA and GI. Prior to that, Li worked in Bristol-Myers Squibb as Lead Statistician to support multiple NDAs, SNDAs and ROW submissions for blockbusters Eliquis and Onglyza in Cardiovascular and Metabolic Therapeutic Areas.  He is enthusiastic in teaching statistical courses to non-statisticians and promoting novel statistical methodologies. He is also active in statistical communities as chair of ICSA Midwest Chapter and executive committee for DIA VJC.